Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Differential Sensitivity of 5'UTR-NS5A Recombinants of Hepatitis C Virus Genotypes 1-6 to Protease and NS5A Inhibitors

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. CO-HEP; Copenhagen Hepatitis C Program

    Projekt: Typer af projekter

  1. Cancer Risk in Pediatric-Onset Inflammatory Bowel Disease: A Population-Based Danish Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Antibody Responses to Immunization With HCV Envelope Glycoproteins as a Baseline for B cell-Based Vaccine Development

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Crohn's Disease With Progressive Renal Impairment

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  4. Safety of Proton Pump Inhibitors Based on a Large, Multi-year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Remission of bile acid malabsorption symptoms following treatment with the glucagon-like peptide 1 receptor agonist liraglutide

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Development of a downstream process for the production of an inactivated whole hepatitis C virus vaccine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Global and local envelope protein dynamics of hepatitis C virus determine broad antibody sensitivity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. An alternate conformation of HCV E2 neutralizing face as an additional vaccine target

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
Hepatitis C virus (HCV) therapy will benefit from the preclinical evaluation of direct-acting antiviral (DAA) agents in infectious culture systems that test the effects on different virus genotypes. We developed HCV recombinants comprising the 5'UTR-NS5A (5-5A) from genotypes 1-6 and 2a(JFH1) NS5B-3'UTR, and tested the effects of NS3 protease and NS5A inhibitors on these recombinants.
OriginalsprogEngelsk
TidsskriftGastroenterology
Vol/bind146
Udgave nummer3
Sider (fra-til)812-821
Antal sider10
ISSN0016-5085
DOI
StatusUdgivet - mar. 2014

ID: 42082817